Subcutaneous ketamine infusion in palliative patients for major depressive disorder (SKIPMDD)-Phase II single-arm open-label feasibility study.
Wei LeeCaitlin SheehanRichard ChyeSungwon ChangAdam BayesColleen LooBrian DraperMeera R AgarDavid C CurrowPublished in: PloS one (2023)
A future definitive trial exploring the effectiveness of subcutaneous infusion of ketamine for major depressive disorder in the palliative care setting may be feasible by addressing identified study barriers. Individual dose-titration of subcutaneous ketamine infusions over two hours from 0.1mg/kg can be well-tolerated and appears to produce transient antidepressant signals over hours to days.
Keyphrases
- major depressive disorder
- phase ii
- open label
- bipolar disorder
- palliative care
- clinical trial
- phase iii
- end stage renal disease
- pain management
- low dose
- advanced cancer
- study protocol
- ejection fraction
- newly diagnosed
- chronic kidney disease
- randomized controlled trial
- systematic review
- phase ii study
- placebo controlled
- double blind
- prognostic factors
- current status
- patient reported outcomes
- radiation therapy
- chronic pain
- brain injury
- blood brain barrier